GlaxoSmithKline says five late-stage trials meet main goal
(Reuters) - GlaxoSmithKline Plc said results from five late-stage trials of two experimental quadrivalent influenza vaccines (QIV) met the main goal of protecting against mild as well as moderate-severe cases of influenza.
GSK said its experimental vaccines contain two influenza A strains and two influenza B strains to potentially help broaden protection against seasonal influenza, compared to approved trivalent vaccines that contain two A influenza strains and one B influenza strain.
(Reporting by Monika Shinghal in Bangalore)
- Tweet this
- Share this
- Digg this
- Taxis, planes and viruses: How deadly Ebola can spread
- Israel looks for missing soldier; Hamas says he may have been killed |
- Experts recover human remains at Ukraine crash site despite new fighting
- Campaign for an independent Scotland stalls before historic vote
- Gaza truce over, Israel soldier captured, 70 dead in Rafah shelling |